2022
PUMILIO proteins promote colorectal cancer growth via suppressing p21
Gong Y, Liu Z, Yuan Y, Yang Z, Zhang J, Lu Q, Wang W, Fang C, Lin H, Liu S. PUMILIO proteins promote colorectal cancer growth via suppressing p21. Nature Communications 2022, 13: 1627. PMID: 35338151, PMCID: PMC8956581, DOI: 10.1038/s41467-022-29309-1.Peer-Reviewed Original ResearchConceptsColorectal cancerAOM/DSS modelIntestine-specific knockoutColitis-associated cancerHuman CRC cellsOrthotopic colon cancer modelColorectal cancer growthG1/S transitionHuman colorectal cancerColorectal tumor growthColon cancer modelCancer cell growthCRC progressionCRC cellsIntravenous injectionTherapeutic targetCancer growthCancer modelTumor growthSignificant decreaseS transitionDirect targetP21 mRNACancerDSS model
2020
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Sun N, Ren C, Kong Y, Zhong H, Chen J, Li Y, Zhang J, Zhou Y, Qiu X, Lin H, Song X, Yang X, Jiang B. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. European Journal Of Medicinal Chemistry 2020, 193: 112190. PMID: 32179332, DOI: 10.1016/j.ejmech.2020.112190.Peer-Reviewed Original ResearchMeSH KeywordsAnaplastic Lymphoma KinaseAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug DevelopmentDrug Resistance, NeoplasmDrug Screening Assays, AntitumorHEK293 CellsHumansLung NeoplasmsMolecular Docking SimulationMolecular StructureProtein Kinase InhibitorsStructure-Activity RelationshipConceptsAnaplastic large cell lymphomaCell lung cancerLung cancerALK proteinNon-small cell lung cancerDrug resistanceSmall cell lung cancerLarge cell lymphomaPotential therapeutic strategyAnti-proliferation abilityCell linesNPM-ALK fusion proteinT cell linesCancer cell linesEML4-ALKCancer regressionTherapeutic strategiesPotential treatmentGrowth inhibition effectInhibitor drugsALK activityCancerCancer resistanceBrigatinibLymphoma
2007
Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation
Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-Miyagawa S, Nakano T, Yates AJ, Carson WE, Lin H, Barsky SH, Gao JX. Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation. PLOS ONE 2007, 2: e293. PMID: 17356702, PMCID: PMC1808425, DOI: 10.1371/journal.pone.0000293.Peer-Reviewed Original ResearchConceptsCancer stem cellsMalignant differentiationPrecancerous stem cellsStem cellsImmunocompetent miceImmunodeficient miceSolid cancersSolid tumorsTherapy of cancerC-kitNovel targetCancerEarly detectionCancer cellsSca-1Lineage markersTissue cellsMicePCSCsCellsSingle cloneDifferentiationTherapyTumorsPrevention